{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:26:06Z","timestamp":1787682366460,"version":"build-2784847793"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["grant agreement No. 948959"],"award-info":[{"award-number":["grant agreement No. 948959"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["grant agreement No. 948959"],"award-info":[{"award-number":["grant agreement No. 948959"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["grant agreement No. 948959"],"award-info":[{"award-number":["grant agreement No. 948959"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["grant agreement No. 948959"],"award-info":[{"award-number":["grant agreement No. 948959"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["grant agreement No. 948959"],"award-info":[{"award-number":["grant agreement No. 948959"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FWO Vlaanderen","award":["11E0123N"],"award-info":[{"award-number":["11E0123N"]}]},{"name":"FWO Vlaanderen","award":["G0B5120N"],"award-info":[{"award-number":["G0B5120N"]}]},{"name":"FWO Vlaanderen","award":["G0B5120N"],"award-info":[{"award-number":["G0B5120N"]}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C16\/18\/007"],"award-info":[{"award-number":["C16\/18\/007"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C16\/18\/007"],"award-info":[{"award-number":["C16\/18\/007"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C16\/18\/007"],"award-info":[{"award-number":["C16\/18\/007"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C16\/18\/007"],"award-info":[{"award-number":["C16\/18\/007"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001245","name":"The Jeffrey Modell Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001245","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>In this review, an update is provided on the current knowledge and pending questions about human adenosine deaminase type 2 deficiency. Patients have vasculitis, immunodeficiency and some have bone marrow failure. Although the condition was described ten years ago, the pathophysiology is incompletely understood<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Endothelial instability due to increased proinflammatory macrophage development is key to the pathophysiology. However, the physiological role of ADA2 is a topic of debate as it is hypothesized that ADA2 fulfils an intracellular role. Increasing our knowledge is urgently needed to design better treatments for the bone marrow failure. Indeed, TNFi treatment has been successful in treating DADA2, except for the bone marrow failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Major advances have been made in our understanding of DADA2. More research is needed into the physiological role of ADA2<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11882-024-01163-9","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T09:01:44Z","timestamp":1720256504000},"page":"477-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Human ADA2 Deficiency: Ten Years Later"],"prefix":"10.1007","volume":"24","author":[{"given":"Marjon","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariia","family":"Dzhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Kienapfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Bucciol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selket","family":"Delafontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneleen","family":"Hombrouck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Moens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"issue":"7","key":"1163_CR1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","volume":"42","author":"SG Tangye","year":"2022","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42(7):1473\u2013507.","journal-title":"J Clin Immunol"},{"issue":"10","key":"1163_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"1163_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJMoa1307362","volume":"370","author":"P Navon Elkan","year":"2014","unstructured":"Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921\u201331.","journal-title":"N Engl J Med"},{"issue":"5","key":"1163_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10875-018-0525-8","volume":"38","author":"I Meyts","year":"2018","unstructured":"Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): Updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569\u201378.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1163_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/BOR.0000000000000669","volume":"32","author":"S Sahin","year":"2020","unstructured":"Sahin S, Adrovic A, Kasapcopur O. A monogenic autoinflammatory disease with fatal vasculitis: deficiency of adenosine deaminase 2. Curr Opin Rheumatol. 2020;32(1):3\u201314.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"1163_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12722","volume":"287","author":"L Moens","year":"2019","unstructured":"Moens L, Hershfield M, Arts K, Aksentijevich I, Meyts I. Human adenosine deaminase 2 deficiency: A multi-faceted inborn error of immunity. Immunol Rev. 2019;287(1):62\u201372.","journal-title":"Immunol Rev"},{"issue":"6","key":"1163_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/03009742.2021.1881156","volume":"50","author":"A Betrains","year":"2021","unstructured":"Betrains A, Staels F, Moens L, Delafontaine S, Hershfield MS, Blockmans D, et al. Diagnosis of deficiency of adenosine deaminase type 2 in adulthood. Scand J Rheumatol. 2021;50(6):493\u20136.","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"1163_CR8","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41431-018-0130-6","volume":"26","author":"M Rama","year":"2018","unstructured":"Rama M, Duflos C, Melki I, Bessis D, Bonhomme A, Martin H, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. Eur J Hum Genet. EJHG. 2018;26(7):960\u201371.","journal-title":"Eur J Hum Genet. EJHG."},{"issue":"4","key":"1163_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.revmed.2017.11.006","volume":"39","author":"A Fayand","year":"2017","unstructured":"Fayand A, Sarrabay G, Belot A, Hentgen V, Kone-Paut I, Grateau G, et al. Multiple facets of ADA2 deficiency: Vasculitis, auto-inflammatory disease and immunodeficiency: A literature review of 135 cases from literature. Rev Med Interne. 2017;39(4):297\u2013306.","journal-title":"Rev Med Interne."},{"issue":"1","key":"1163_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaci.2021.04.034","volume":"149","author":"H Jee","year":"2022","unstructured":"Jee H, Huang Z, Baxter S, Huang Y, Taylor ML, Henderson LA, et al. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. J Allergy Clin Immunol. 2022;149(1):379\u201387.","journal-title":"J Allergy Clin Immunol"},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"811473","DOI":"10.3389\/fimmu.2021.811473","volume":"12","author":"KS Barron","year":"2021","unstructured":"Barron KS, Aksentijevich I, Deuitch NT, Stone DL, Hoffmann P, Videgar-Laird R, et al. The spectrum of the deficiency of adenosine deaminase 2: An observational analysis of a 60 patient cohort. Front Immunol. 2021;12:811473.","journal-title":"Front Immunol"},{"issue":"7","key":"1163_CR12","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10875-021-01098-0","volume":"41","author":"H Hashem","year":"2021","unstructured":"Hashem H, Bucciol G, Ozen S, Unal S, Bozkaya IO, Akarsu N, et al. Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: Report on 30 patients. J Clin Immunol. 2021;41(7):1633\u201347.","journal-title":"J Clin Immunol"},{"key":"1163_CR13","first-page":"932385","volume":"13","author":"H Hashem","year":"2022","unstructured":"Hashem H, Dimitrova D, Meyts I. Allogeneic hematopoietic cell transplantation for patients with deficiency of adenosine deaminase 2 (DADA2): Approaches. Obstacles and Special Considerations Front Immunol. 2022;13:932385.","journal-title":"Obstacles and Special Considerations Front Immunol"},{"issue":"5","key":"1163_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.15894","volume":"6","author":"PY Lee","year":"2023","unstructured":"Lee PY, Davidson BA, Abraham RS, Alter B, Arostegui JI, Bell K, et al. Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement. JAMA Netw Open. 2023;6(5): e2315894.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1163_CR15","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1007\/s10875-023-01555-y","volume":"43","author":"M Dzhus","year":"2023","unstructured":"Dzhus M, Ehlers L, Wouters M, Jansen K, Schrijvers R, De Somer L, et al. A narrative review of the neurological manifestations of human adenosine deaminase 2 deficiency. J Clin Immunol. 2023;43(8):1916\u201326.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1163_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16043","volume":"31","author":"MA Verschoof","year":"2024","unstructured":"Verschoof MA, van Meenen LCC, Andriessen MVE, Brinkman DMC, Kamphuis S, Kuijpers TW, et al. Neurological phenotype of adenosine deaminase 2 deficient patients: a cohort study. Eur J Neurol. 2024;31(1): e16043.","journal-title":"Eur J Neurol"},{"issue":"7","key":"1163_CR17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s10875-023-01521-8","volume":"43","author":"MVE Andriessen","year":"2023","unstructured":"Andriessen MVE, Legger GE, Bredius RGM, van Gijn ME, Hak AE, Muller P, et al. Clinical symptoms, laboratory parameters and long-term follow-up in a national DADA2 cohort. J Clin Immunol. 2023;43(7):1581\u201396.","journal-title":"J Clin Immunol"},{"key":"1163_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937108","volume":"13","author":"E Drago","year":"2022","unstructured":"Drago E, Garbarino F, Signa S, Grossi A, Schena F, Penco F, et al. Case Report: Susceptibility to viral infections and secondary hemophagocytic lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of adenosine deaminase 2 deficiency. Front Immunol. 2022;13: 937108.","journal-title":"Front Immunol"},{"issue":"1","key":"1163_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10875-019-0590-7","volume":"39","author":"F Alabbas","year":"2019","unstructured":"Alabbas F, Elyamany G, Alsharif O, Hershfield M, Meyts I. Childhood hodgkin lymphoma: Think DADA2. J Clin Immunol. 2019;39(1):26\u20139.","journal-title":"J Clin Immunol"},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2018.01.012","volume":"141","author":"L Trotta","year":"2018","unstructured":"Trotta L, Martelius T, Siitonen T, Hautala T, Hamalainen S, Juntti H, et al. ADA2 deficiency: Clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol. 2018;141:1534\u20131537.e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1163_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-016-0245-x","volume":"36","author":"J Schepp","year":"2016","unstructured":"Schepp J, Bulashevska A, Mannhardt-Laakmann W, Cao H, Yang F, Seidl M, et al. Deficiency of adenosine deaminase 2 causes antibody deficiency. J Clin Immunol. 2016;36(3):179\u201386.","journal-title":"J Clin Immunol"},{"issue":"8","key":"1163_CR22","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/art.40147","volume":"69","author":"J Schepp","year":"2017","unstructured":"Schepp J, Proietti M, Frede N, Buchta M, Hubscher K, Rojas Restrepo J, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69(8):1689\u2013700.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1163_CR23","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s10875-021-01141-0","volume":"41","author":"JY Yap","year":"2021","unstructured":"Yap JY, Moens L, Lin M-W, Kane A, Kelleher A, Toong C, et al. Intrinsic defects in B cell development and differentiation, T cell exhaustion and altered unconventional T cell generation characterize human adenosine deaminase type 2 deficiency. J Clin Immunol. 2021;41(8):1915\u201335.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1163_CR24","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s10875-020-00812-8","volume":"40","author":"T Le Voyer","year":"2020","unstructured":"Le Voyer T, Boutboul D, Ledoux-Pilon A, de Fontbrune FS, Boursier G, Latour S, et al. Late-onset EBV susceptibility and refractory pure red cell aplasia revealing DADA2. J Clin Immunol. 2020;40(6):948\u201353.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1163_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s10875-020-00940-1","volume":"41","author":"JP Brooks","year":"2021","unstructured":"Brooks JP, Rice AJ, Ji W, Lanahan SM, Konstantino M, Dara J, et al. Uncontrolled epstein-barr virus as an atypical presentation of deficiency in ADA2 (DADA2). J Clin Immunol. 2021;41(3):680\u20133.","journal-title":"J Clin Immunol."},{"key":"1163_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108443","volume":"215","author":"E Staples","year":"2020","unstructured":"Staples E, Simeoni I, Stephens JC, Allen HL, BioResource N, Wright P, et al. ADA2 deficiency complicated by EBV-driven lymphoproliferative disease. Clinical immunology (Orlando, Fla). 2020;215: 108443.","journal-title":"Clinical immunology (Orlando, Fla)"},{"issue":"9","key":"1163_CR27","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood.2019000928","volume":"135","author":"SG Tangye","year":"2020","unstructured":"Tangye SG, Latour S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood. 2020;135(9):644\u201355.","journal-title":"Blood"},{"issue":"3","key":"1163_CR28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s10875-022-01413-3","volume":"43","author":"L Ehlers","year":"2023","unstructured":"Ehlers L, Bucciol G, team KUL-UD, Beysen D, Meyts I. ADA2 Deficiency mimicking acute disseminated encephalomyelitis. J Clin Immunol. 2023;43(3):536\u20139.","journal-title":"J Clin Immunol"},{"issue":"6","key":"1163_CR29","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","volume":"145","author":"PY Lee","year":"2020","unstructured":"Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020;145(6):1664-72e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"1163_CR30","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMc1801927","volume":"380","author":"AK Ombrello","year":"2019","unstructured":"Ombrello AK, Qin J, Hoffmann PM, Kumar P, Stone D, Jones A, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med. 2019;380(16):1582\u20134.","journal-title":"N Engl J Med"},{"key":"1163_CR31","unstructured":"Ombrello AK BK, Hoffmann P, Toro C, Stone DL, Pinto-Patarroyo G, Jones A, Romeo T, Soldatos A, Zhou Q, Deuitch N, Qin J, Aksentijevich I, Kastner DL. Deficiency of adenosine deaminase type 2 (DADA2)\u2014results of anti-TNF treatment in a cohort of patients with a history of stroke. Arthritis Rheumatol. 2016;68(S10)."},{"issue":"24","key":"1163_CR32","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1182\/blood-2017-07-798660","volume":"130","author":"H Hashem","year":"2017","unstructured":"Hashem H, Kumar AR, Muller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017;130(24):2682\u20138.","journal-title":"Blood"},{"issue":"3","key":"1163_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00281-022-00918-8","volume":"44","author":"PY Lee","year":"2022","unstructured":"Lee PY, Aksentijevich I, Zhou Q. Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (DADA2). Semin Immunopathol. 2022;44(3):269\u201380.","journal-title":"Semin Immunopathol"},{"issue":"30","key":"1163_CR34","doi-asserted-by":"publisher","first-page":"eaba3688","DOI":"10.1126\/sciadv.aba3688","volume":"6","author":"R Dhanwani","year":"2020","unstructured":"Dhanwani R, Takahashi M, Mathews IT, Lenzi C, Romanov A, Watrous JD, et al. Cellular sensing of extracellular purine nucleosides triggers an innate IFN-beta response. Sci Adv. 2020;6(30):eaba3688.","journal-title":"Sci Adv"},{"issue":"4","key":"1163_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","volume":"134","author":"C Carmona-Rivera","year":"2019","unstructured":"Carmona-Rivera C, Khaznadar SS, Shwin KW, Irizarry-Caro JA, O\u2019Neil LJ, Liu Y, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood. 2019;134(4):395\u2013406.","journal-title":"Blood"},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1546-0096-12-44","volume":"12","author":"A Belot","year":"2014","unstructured":"Belot A, Wassmer E, Twilt M, Lega JC, Zeef LA, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014;12:44.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"1163_CR37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3899\/jrheum.180045","volume":"46","author":"A Insalaco","year":"2019","unstructured":"Insalaco A, Moneta GM, Pardeo M, Caiello I, Messia V, Bracaglia C, et al. Variable clinical phenotypes and relation of interferon signature with disease activity in ADA2 deficiency. J Rheumatol. 2019;46(5):523\u20136.","journal-title":"J Rheumatol"},{"issue":"1","key":"1163_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12969-017-0193-x","volume":"15","author":"A Skrabl-Baumgartner","year":"2017","unstructured":"Skrabl-Baumgartner A, Plecko B, Schmidt WM, Konig N, Hershfield M, Gruber-Sedlmayr U, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol Online J. 2017;15(1):67.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"1163_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jaci.2021.01.018","volume":"148","author":"H Nihira","year":"2021","unstructured":"Nihira H, Izawa K, Ito M, Umebayashi H, Okano T, Kajikawa S, et al. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation. J Allergy Clin Immunol. 2021;148(2):550\u201362.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"1163_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jaci.2023.04.014","volume":"152","author":"L Chen","year":"2023","unstructured":"Chen L, Mamutova A, Kozlova A, Latysheva E, Evgeny F, Latysheva T, et al. Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2. J Allergy Clin Immunol. 2023;152(3):771\u201382.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1163_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10875-023-01638-w","volume":"44","author":"G Bucciol","year":"2023","unstructured":"Bucciol G, Ombrello AK, Chambers EP, Meyts I. Proposal for a Disease Activity Score and Disease Damage Score for ADA2 Deficiency: the DADA2AI and DADA2DI. J Clin Immunol. 2023;44(1):25.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1163_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1073\/pnas.75.1.446","volume":"75","author":"WP Schrader","year":"1978","unstructured":"Schrader WP, Pollara B, Meuwissen HJ. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci USA. 1978;75(1):446\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1163_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1006\/geno.1999.6099","volume":"64","author":"MA Riazi","year":"2000","unstructured":"Riazi MA, Brinkman-Mills P, Nguyen T, Pan H, Phan S, Ying F, et al. The human homolog of insect-derived growth factor, CECR1, is a candidate gene for features of cat eye syndrome. Genomics. 2000;64(3):277\u201385.","journal-title":"Genomics"},{"issue":"16","key":"1163_CR44","doi-asserted-by":"publisher","first-page":"12367","DOI":"10.1074\/jbc.M109.083527","volume":"285","author":"AV Zavialov","year":"2010","unstructured":"Zavialov AV, Yu X, Spillmann D, Lauvau G, Zavialov AV. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem. 2010;285(16):12367\u201377.","journal-title":"J Biol Chem"},{"issue":"4","key":"1163_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0301-0082(97)00013-0","volume":"52","author":"R Franco","year":"1997","unstructured":"Franco R, Casado V, Ciruela F, Saura C, Mallol J, Canela EI, et al. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol. 1997;52(4):283\u201394.","journal-title":"Prog Neurobiol"},{"issue":"4","key":"1163_CR46","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.jaci.2018.05.038","volume":"142","author":"PY Lee","year":"2018","unstructured":"Lee PY, Huang Y, Zhou Q, Schnappauf O, Hershfield MS, Li Y, et al. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. J Allergy Clin Immunol. 2018;142(4):1363\u20131365.e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1163_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2022.130237","volume":"1866","author":"M Ito","year":"2022","unstructured":"Ito M, Maejima Y, Nishimura K, Nakae Y, Ono A, Iwaki-Egawa S. A role for N-glycosylation in active adenosine deaminase 2 production. Biochim Biophys Acta Gen Subj. 2022;1866(12): 130237.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"11\u201312","key":"1163_CR48","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/21678707.2021.2050367","volume":"9","author":"TK Tarrant","year":"2021","unstructured":"Tarrant TK, Kelly SJ, Hershfield MS. Elucidating the pathogenesis of adenosine deaminase 2 deficiency: current status and unmet needs. Expert Opin Orphan Drugs. 2021;9(11\u201312):257\u201364.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"10","key":"1163_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205707","volume":"13","author":"L Lofgren","year":"2018","unstructured":"Lofgren L, Pehrsson S, Hagglund G, Tjellstrom H, Nylander S. Accurate measurement of endogenous adenosine in human blood. PLoS ONE. 2018;13(10): e0205707.","journal-title":"PLoS ONE"},{"issue":"5","key":"1163_CR50","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","volume":"447","author":"SA Baldwin","year":"2004","unstructured":"Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004;447(5):735\u201343.","journal-title":"Pflugers Arch"},{"key":"1163_CR51","doi-asserted-by":"publisher","unstructured":"Greiner-Tollersrud OK, Boehler V, Bartok E, Krausz M, Polyzou A, Schepp J, et al. ADA2 is a lysosomal DNase regulating the type-I interferon response. 2020. BioRxiv.\u00a0https:\/\/doi.org\/10.1101\/2020.06.21.162990.","DOI":"10.1101\/2020.06.21.162990"},{"key":"1163_CR52","doi-asserted-by":"crossref","unstructured":"Ehlers L,\u00a0Hombrouck A, Wouters M, Pillay B, Delafontaine S, Bucciol G,\u00a0et al. Human ADA2 deficiency is characterized by the absence of an intracellular hypoglycosylated form of adenosine deaminase 2 BioRXiv bioRxiv 2023. 10.25.5640372023 [updated 2023].","DOI":"10.1101\/2023.10.25.564037"},{"issue":"6","key":"1163_CR53","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","volume":"123","author":"MA Spinner","year":"2014","unstructured":"Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809\u201321.","journal-title":"Blood"},{"issue":"2","key":"1163_CR54","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaci.2016.03.016","volume":"138","author":"AP Hsu","year":"2016","unstructured":"Hsu AP, West RR, Calvo KR, Cueller-Rodriguez J, Parta M, Kelly SJ, et al. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency Successful hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2016;138(2):628-30e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"1163_CR55","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s10875-018-0565-0","volume":"38","author":"K Arts","year":"2018","unstructured":"Arts K, Bergerson JRE, Ombrello AK, Similuk M, Oler AJ, Agharahimi A, et al. Warts and DADA2: a Mere Coincidence? J Clin Immunol. 2018;38(8):836\u201343.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1163_CR56","doi-asserted-by":"publisher","first-page":"8305","DOI":"10.1038\/s41598-020-64852-1","volume":"10","author":"AA Amarnani","year":"2020","unstructured":"Amarnani AA, Poladian KR, Marciano BE, Daub JR, Williams SG, Livinski AA, et al. A Panoply of Rheumatological Manifestations in Patients with GATA2 Deficiency. Sci Rep. 2020;10(1):8305.","journal-title":"Sci Rep"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01163-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01163-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01163-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T11:37:02Z","timestamp":1725017822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01163-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01163-9","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"26 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments involving human or animal subjects performed by the authors were in accordance with the ethical standards of institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Meyts reports grants and other from CSL-behring, other from Boehringer-Ingelheim, other from Takeda, grants and other from Octapharma,  outside the submitted work;  In addition, Dr. Meyts has a patent EP23201683.2 pending to KU Leuven.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}